Stamford Pharmaceuticals Inc announces the first patient to be treated with SP-002 in combination with Erivedge® in a Phase 2 Study in locally advanced BCC subjects.
Stamford Pharmaceuticals Inc, a clinical-stage biotechnology company developing science-driven immune therapies, today announced initiation of its locally advanced basal cell carcinoma (laBCC) trial (NCT06344052). The study will evaluate SP-002, an adenoviral-based immunotherapy, in combination with Roche’s vismodegib (Erivedge®), a Hedgehog Pathway inhibitor (HHPI), approved for the treatment of adult patients presenting with locally advanced and metastatic basal cell carcinoma. The phase 2 clinical study is funded with proceeds from a Series A led by Tenmile Ventures, Prevail Partners and other syndicate parties completed in October 2023.
“We are excited to progress SP-002 in combination with HHPI into this subset of locally advanced BCC patients. This study was motivated by encouraging results observed in clinical studies evaluating SP-002 as a monotherapy or in combination with HHPI in other BCC settings. We believe there is an opportunity to further improve patient benefit in locally advanced BCC patients based on the current standard of care.” said Clement Leong, PhD., CEO of Stamford Pharmaceuticals.